Orphan drug designation (ODD)

Orphan drug designation (ODD) is a regulatory status granted to a medicinal product intended to diagnose, prevent or treat a rare, life-threatening or chronically debilitating condition. In the EU, Regulation (EC) No 141/2000 sets the criteria: the condition affects no more than 5 in 10,000 people in the Union (or the product would not be developed without incentives), and there is no satisfactory authorised method, or the product would be of significant benefit over existing methods. Designation is granted by the European Commission on the opinion of the EMA's Committee for Orphan Medicinal Products. In the United States the Orphan Drug Act of 1983 applies to conditions affecting fewer than 200,000 people, with designation by the FDA's Office of Orphan Products Development.

Incentives include protocol assistance and fee reductions, access to the centralised procedure, and ten years of market exclusivity in the EU (seven in the US), extended for paediatric investigations. The EU pharmaceutical package under negotiation proposes to modulate exclusivity periods. Designation is reviewed at the time of marketing authorisation to confirm the criteria are still met.

Rare-disease development has a distinctive data protection profile. Small, well-characterised populations make anonymisation of trial results and registry data difficult, so data is almost always pseudonymised personal data. Genetic data is central, patient organisations and natural history registries act as data sources and sometimes as joint controllers, and global recruitment means extensive international transfers. Publication of results and transparency obligations must be balanced against re-identification risk through careful aggregation.